Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study

20176 citationsJournal Articlehybrid Open Access

Authors

Karel Kostev · Industrial & Marine Service (Germany)

Stefan Pscherer · Sophien-und Hufeland Klinikum

Markus F. Scheerer · AstraZeneca (Germany)

Abstract

Initiation of dapagliflozin therapy reduced HbA1c similar to basal insulin with the additional benefit of weight reduction in type 2 diabetes patients treated in general practices.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Diabetes Science and Technology

Volume 11, Issue 3, pp. 590-596

DOI: 10.1177/1932296816688011

Field-Weighted Citation Impact: 0.71